BRPI0712561B8 - Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida - Google Patents

Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida

Info

Publication number
BRPI0712561B8
BRPI0712561B8 BRPI0712561A BRPI0712561A BRPI0712561B8 BR PI0712561 B8 BRPI0712561 B8 BR PI0712561B8 BR PI0712561 A BRPI0712561 A BR PI0712561A BR PI0712561 A BRPI0712561 A BR PI0712561A BR PI0712561 B8 BRPI0712561 B8 BR PI0712561B8
Authority
BR
Brazil
Prior art keywords
foot
mouth disease
dihydro
oxo
sheep
Prior art date
Application number
BRPI0712561A
Other languages
English (en)
Inventor
Yousuke Furuta
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of BRPI0712561A2 publication Critical patent/BRPI0712561A2/pt
Publication of BRPI0712561B1 publication Critical patent/BRPI0712561B1/pt
Publication of BRPI0712561B8 publication Critical patent/BRPI0712561B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

agente antiviral da doença da febre aftosa, método de tratamento de doença da febre aftosa, alimento para uma ovelha, e, método preventivo ou terapêutico para doença da febre aftosa. é descrito um agente antiviral da doença da febre aftosa para um animal que pertence à família suidae, que compreende 3-oxo-3,4-diidro-2pirazincarboxamida ou um sal do mesmo. o agente é extremamente usado para a prevenção ou tratamento da doença da febre aftosa em um animal que pertence à família suidae. também é descrito um agente antiviral da doença da febre aftosa para ovelha, que compreende 3-oxo-3,4-diidro-2-pirazincarboxamida ou um sal do mesmo. o agente é extremamente usado para a prevenção, terapia ou similares da doença da febre aftosa em ovelha.
BRPI0712561A 2006-05-31 2007-05-29 Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida BRPI0712561B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2006151903 2006-05-31
JP2006-151903 2006-05-31
JP2006-247698 2006-09-13
JP2006247698 2006-09-13
PCT/JP2007/060851 WO2007139081A1 (ja) 2006-05-31 2007-05-29 イノシシ科動物またはヒツジ用抗口蹄疫ウイルス剤およびイノシシ科動物またはヒツジの口蹄疫の予防または治療方法

Publications (3)

Publication Number Publication Date
BRPI0712561A2 BRPI0712561A2 (pt) 2012-11-20
BRPI0712561B1 BRPI0712561B1 (pt) 2023-10-24
BRPI0712561B8 true BRPI0712561B8 (pt) 2023-12-26

Family

ID=38778601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712561A BRPI0712561B8 (pt) 2006-05-31 2007-05-29 Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida

Country Status (21)

Country Link
US (1) US8815842B2 (pt)
EP (1) EP2022786B1 (pt)
JP (1) JP5161078B2 (pt)
KR (1) KR101388061B1 (pt)
CN (1) CN101454295B (pt)
AT (1) ATE530532T1 (pt)
AU (1) AU2007268684B2 (pt)
BR (1) BRPI0712561B8 (pt)
CA (1) CA2653933C (pt)
CY (1) CY1112063T1 (pt)
DK (1) DK2022786T3 (pt)
ES (1) ES2373469T3 (pt)
MX (1) MX2008015181A (pt)
MY (1) MY147152A (pt)
NZ (1) NZ573108A (pt)
PL (1) PL2022786T3 (pt)
PT (1) PT2022786E (pt)
RU (1) RU2428187C2 (pt)
SI (1) SI2022786T1 (pt)
WO (1) WO2007139081A1 (pt)
ZA (1) ZA200810107B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617491B (zh) * 2011-07-01 2015-05-06 中国人民解放军军事医学科学院毒物药物研究所 3-氧代-3,4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途
WO2013004092A1 (zh) * 2011-07-01 2013-01-10 中国人民解放军军事医学科学院毒物药物研究所 3-氧代-3，4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途
WO2013004141A1 (zh) * 2011-07-01 2013-01-10 中国人民解放军军事医学科学院毒物药物研究所 3－烷氧基取代－2－吡嗪甲酰氨类化合物及其用途
CN102846617B (zh) * 2011-07-01 2016-01-13 中国人民解放军军事医学科学院毒物药物研究所 3－(丁基氧基)－2－吡嗪甲酰氨的制备方法和用途
KR101690452B1 (ko) 2016-01-20 2016-12-27 오형근 친환경 효소를 함유한 조성물 제조방법 및 가축용 사료
CN107439792A (zh) * 2017-07-01 2017-12-08 山东阳春羊奶乳业有限公司 一种防治奶山羊口炎的发酵饲料及其制备方法
KR102250830B1 (ko) * 2020-07-17 2021-05-11 주식회사 농업회사법인 케이푸드 유황 돼지 사료
KR102671165B1 (ko) 2021-05-24 2024-06-03 경성대학교 산학협력단 마크로락틴 유도체, 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 구제역 바이러스의 감염 질환 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2927027A (en) * 1957-11-20 1960-03-01 Du Pont Feed efficiency promoting composition
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
DE3508258A1 (de) 1985-03-08 1986-09-18 Bayer Ag, 5090 Leverkusen Ss-lactamantibiotika, verfahren zur herstellung und ihre verwendung als und in arzneimitteln
RU2061474C1 (ru) * 1992-04-20 1996-06-10 Всесоюзный научно-исследовательский ящурный институт Средство, обладающее противоящурной активностью
GB9401787D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
JP2000007564A (ja) * 1997-07-16 2000-01-11 Eisai Co Ltd インドール誘導体を含む抗生剤
PL200955B1 (pl) 1998-08-20 2009-02-27 Toyama Chemical Co Ltd Przeciwwirusowa kompozycja farmaceutyczna i jej zastosowanie oraz zawierająca azot heterocykliczna pochodna karboksamidu
ATE294185T1 (de) 2000-02-16 2005-05-15 Toyama Chemical Co Ltd Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediäre zur herstellung der derivate
DE10105306A1 (de) 2001-02-02 2002-08-22 Nutrinova Gmbh Futtermittel für die Nutztieraufzucht enthaltend Sorbinsäure und Enzyme
EP1399132A1 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Production of hard, dense particles

Also Published As

Publication number Publication date
PL2022786T3 (pl) 2012-06-29
AU2007268684A8 (en) 2009-01-08
CN101454295B (zh) 2011-09-21
KR101388061B1 (ko) 2014-04-22
AU2007268684B2 (en) 2012-02-23
JP5161078B2 (ja) 2013-03-13
KR20090027664A (ko) 2009-03-17
ZA200810107B (en) 2010-02-24
ATE530532T1 (de) 2011-11-15
WO2007139081A1 (ja) 2007-12-06
MY147152A (en) 2012-11-14
CA2653933A1 (en) 2007-12-06
NZ573108A (en) 2011-02-25
ES2373469T3 (es) 2012-02-03
BRPI0712561B1 (pt) 2023-10-24
PT2022786E (pt) 2012-01-04
CY1112063T1 (el) 2015-11-04
US20090156580A1 (en) 2009-06-18
MX2008015181A (es) 2008-12-09
EP2022786A4 (en) 2010-07-28
CN101454295A (zh) 2009-06-10
SI2022786T1 (sl) 2012-04-30
RU2008152376A (ru) 2010-07-10
JPWO2007139081A1 (ja) 2009-10-08
US8815842B2 (en) 2014-08-26
AU2007268684A1 (en) 2007-12-06
RU2428187C2 (ru) 2011-09-10
EP2022786A1 (en) 2009-02-11
BRPI0712561A2 (pt) 2012-11-20
DK2022786T3 (da) 2012-02-06
EP2022786B1 (en) 2011-10-26
CA2653933C (en) 2013-10-08

Similar Documents

Publication Publication Date Title
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BRPI0511854A (pt) inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
AR064725A1 (es) Profilaxis y tratamiento del complejo respiratorio porcino (prdc). uso
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0916885B8 (pt) composição farmacêutica
BRPI0416731A (pt) métodos para a redução de quantidade de desulfovibrio e/ou helicobacter spp. no trato gi de um animal de estimação, para tratamento de uma inflamação do trato gi em um animal de estimação, e para a redução de um odor
NO20070996L (no) Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser
PT1220676E (pt) Prevencao do cancro colorrectal
BRPI0508333A (pt) uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
AR054435A1 (es) Agente para profilaxis o terapia contra la depresion o desorden de ansiedad
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
BRPI0514193A (pt) agente de diminuição de crp, método para previnir e/ou tratar uma doença envolvida em elevação de crp, e, uso de um composto tendo uma atividade inibitória de esqualeno sintase, ou uma pró-droga do mesmo, ou um sal do mesmo

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07D 241/08 (2006.01), A61P 31/12 (2006.01)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2755 DE24/10/2023, QUANTO AO ITEM (73) NOME DO TITULAR.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.